X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SUN PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SUN PHARMA ASTRAZENECA PHARMA/
SUN PHARMA
 
P/E (TTM) x 105.3 25.9 407.0% View Chart
P/BV x 15.0 3.8 396.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   SUN PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
SUN PHARMA
Mar-17
ASTRAZENECA PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285842 152.6%   
Low Rs634572 110.8%   
Sales per share (Unadj.) Rs189.6131.6 144.0%  
Earnings per share (Unadj.) Rs-0.232.7 -0.6%  
Cash flow per share (Unadj.) Rs3.838.0 10.1%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs68.6152.7 44.9%  
Shares outstanding (eoy) m25.002,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.15.4 94.2%   
Avg P/E ratio x-4,712.721.6 -21,791.0%  
P/CF ratio (eoy) x249.618.6 1,340.1%  
Price / Book Value ratio x14.04.6 301.8%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m23,9881,696,877 1.4%   
No. of employees `0001.617.5 8.9%   
Total wages/salary Rs m1,60549,023 3.3%   
Avg. sales/employee Rs Th3,040.218,028.3 16.9%   
Avg. wages/employee Rs Th1,029.22,798.8 36.8%   
Avg. net profit/employee Rs Th-3.34,479.5 -0.1%   
INCOME DATA
Net Sales Rs m4,740315,784 1.5%  
Other income Rs m926,232 1.5%   
Total revenues Rs m4,832322,016 1.5%   
Gross profit Rs m-130100,893 -0.1%  
Depreciation Rs m10112,648 0.8%   
Interest Rs m03,998 0.0%   
Profit before tax Rs m-13990,479 -0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m512,116 0.0%   
Profit after tax Rs m-578,462 -0.0%  
Gross profit margin %-2.731.9 -8.6%  
Effective tax rate %-3.713.4 -27.4%   
Net profit margin %-0.124.8 -0.4%  
BALANCE SHEET DATA
Current assets Rs m2,726329,537 0.8%   
Current liabilities Rs m2,435178,870 1.4%   
Net working cap to sales %6.147.7 12.9%  
Current ratio x1.11.8 60.8%  
Inventory Days Days7479 93.4%  
Debtors Days Days4183 49.0%  
Net fixed assets Rs m1,035204,766 0.5%   
Share capital Rs m502,399 2.1%   
"Free" reserves Rs m942363,997 0.3%   
Net worth Rs m1,716366,397 0.5%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m4,156614,102 0.7%  
Interest coverage xNM23.6-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.5 221.8%   
Return on assets %-0.113.4 -0.9%  
Return on equity %-0.321.4 -1.4%  
Return on capital %024.8 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37544,118 0.8%   
Fx outflow Rs m47024,484 1.9%   
Net fx Rs m-9619,634 -0.5%   
CASH FLOW
From Operations Rs m-870,822 -0.0%  
From Investments Rs m-146-42,216 0.3%  
From Financial Activity Rs m862-22,854 -3.8%  
Net Cashflow Rs m7096,107 11.6%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.1 5.8%  
FIIs % 15.7 23.0 68.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.3 109.6%  
Shareholders   12,856 133,026 9.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  UNICHEM LAB  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS